Evidence map›Paper›PMID 34252228›Full record

ArticleHealth economics2021

Recreational cannabis laws and opioid-related emergency department visit rates.

Coleman Drake, Jiebing Wen, Jesse Hinde, Hefei Wen

Open access · greenAbstract read
In one paragraph

Article in Health economics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Coleman DrakeDepartment of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania, USA.ORCID 0000-0002-0618-0626
Jiebing WenDepartment of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
Jesse HindeRTI International, Research Triangle Park, North Carolina, USA.
Hefei WenDepartment of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.ORCID 0000-0001-5064-2501
Harvard Pilgrim Health Care · USRTI International · USUniversity of Pittsburgh · US

Funding

Geographic Access to Medication Assisted Treatment for Medicaid Enrollees with Opioid Use DisorderK01DA051761 · NIDA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DRAKE, COLEMAN · 2020 to 2023
$692k
NIDA NIH HHS K01D1051761NIDA NIH HHS K01 DA051761
6 · The paper itself

Abstract

The opioid epidemic in the United States has accelerated during the COVID-19 pandemic. As of 2021, roughly a third of Americans now live in a state with a recreational cannabis law (RCL). Recent evidence indicates RCLs could be a harm reduction tool to address the opioid epidemic. Individuals may use cannabis to manage pain, as well as to relieve opioid withdrawal symptoms, though it does not directly treat opioid use disorder. It is thus unclear whether RCLs are an effective policy tool to reduce adverse opioid-related health outcomes. In this study, we examine the impact of RCLs on a key opioid-related adverse health outcome: opioid-related emergency department (ED) visit rates. We estimate event study models using nearly comprehensive ED data from 29 states from 2011 to 2017. We find that RCLs reduce opioid-related ED visit rates by roughly 7.6% for two quarters after implementation. These effects are driven by men and adults aged 25-44. These effects dissipate after 6 months. Our estimates indicate RCLs did not increase opioid-related ED visits. We conclude that, while cannabis liberalization may offer some help in curbing the opioid epidemic, it is likely not a panacea.

Indexed as

CannabisCOVID-19AdultAnalgesics, OpioidEmergency Service, HospitalHumansMalePandemicsSARS-CoV-2United StatesAnalgesics, Opioidcannabisdifference-in-differencesemergency departmentopioid use disorder

Identifiers

PMID34252228
PMCPMC8985992
OpenAlexW3182041642

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.